How Feehery was paid
$6.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| William F. FeeheryFormer Chief Executive Officer | $795,675 | — | $4,927,502 | $747,935 | $20,275 | $6,491,387 |
| John E. Gallagher IIISenior Vice President and CFO | $606,315 | — | $1,799,603 | $301,043 | $16,890 | $2,723,851 |
| Robert A. AspburyPresident, Certara Predictive Technologies | $457,666 | — | $1,199,743 | $331,386 | $37,073 | $2,025,868 |
| Leif E. PedersenPresident, Chief Commercial Officer | $458,350 | — | $1,199,743 | $214,993 | $16,739 | $1,889,825 |
| Adrian K. McKemeyPresident, Certara Drug Development Solutions | $366,667 | $466,000 | $856,958 | $161,172 | $5,026 | $1,855,823 |
What changed and why
- $6.5MWilliam F. Feehery received total compensation of $6,491,387 for 2025, reflecting a decrease from the prior year.
- Jon Resnick succeeded William F. Feehery as Chief Executive Officer effective January 1, 2026.
- 60%Long-term incentive awards for named executive officers in 2025 comprised 60% performance-based restricted stock units and 40% restricted stock units.
- The ratio of the CEO to median employee annual total compensation was 67 to 1.
- Adrian K. McKemey joined Certara as President of Certara Drug Development Solutions on March 3, 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.